menu
    • menu
    [{"orgOrder":0,"company":"Personalis","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Personalis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Personalis \/ Ono Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Personalis \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Personalis","sponsor":"Olink Proteomics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Personalis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Personalis \/ Olink Proteomics","highestDevelopmentStatusID":"15","companyTruncated":"Personalis \/ Olink Proteomics"},{"orgOrder":0,"company":"Personalis","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"mRNA-4157","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase II","graph3":"Personalis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Personalis \/ Moderna Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Personalis \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Personalis","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Private Placement","leadProduct":"mRNA-4157","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase III","graph3":"Personalis","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Intramuscular Injection","sponsorNew":"Personalis \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Personalis \/ Merck & Co"}]

    Find Clinical Drug Pipeline Developments & Deals by Personalis

    Menu

    Personalis

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Personalis

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Personalis

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : mRNA-4157,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Merck & Co

                            Deal Size : $50.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Personalis Gains Merck Investment and Extends Moderna Collaboration

                            Details : Merck will leverage Personalis' advanced tumor profiling platform to support the clinical development of V940 (mRNA-4157), which is currently being evaluated for Stage II/IIIB NSCLC.

                            Product Name : V940

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            December 19, 2024

                            Lead Product(s) : mRNA-4157,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Merck & Co

                            Deal Size : $50.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Personalis

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Personalis

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Ono Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Personalis, National Cancer Center Hospital East, and Ono Collaborate to Better Predict Immunotherapy Response...

                            Details : The collaboration aims to examine the efficacy and safety of Opdivo, an immune checkpoint inhibitor, for resectable rectal cancer with dMMR. NCCHE will recruit patients and conduct the trial, Ono will provide nivolumab, and Personalis will perform MRD an...

                            Product Name : Opdivo

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            May 16, 2023

                            Lead Product(s) : Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Ono Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Personalis

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Personalis

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : mRNA-4157,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Moderna Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Cli...

                            Details : Under the terms of the agreement, the companies will Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials evaluating mRNA-4157/V940, an investigational personalized cancer vaccine.

                            Product Name : V940

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            March 02, 2023

                            Lead Product(s) : mRNA-4157,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Moderna Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Personalis

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Personalis

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Olink Proteomics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Personalis Forms Research Collaboration to Better Predict Immunotherapy Response for Gastroesophageal Cancer

                            Details : The goal of the collaborative study is to characterize key tumor and immunological responses to pembrolizumab (Keytruda) and, in so doing, shine light on the potential mechanisms that lead to either sensitivity or resistance to immunotherapeutics in gast...

                            Product Name : Keytruda

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            April 10, 2022

                            Lead Product(s) : Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Olink Proteomics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth